# Nuformix plc Official Decision to Grant from the Japanese Patent Office

- Link: https://www.directorstalkinterviews.com/nuformix-plc-official-decision-to-grant-from-the-japanese-patent-office/4121130413
- Published: 2023-10-23T07:14:06+01:00
- Author: Emily Johnson

**Nuformix plc** ([LON: NFX](https://www.directorstalkinterviews.com/company/nuformix-plc/nfx.l)),
a pharmaceutical development company targeting unmet medical needs in fibrosis and
oncology via drug repurposing, has announced that it has been issued with an Official
Decision to Grant Notice of Allowance for Japanese National Phase Patent Application
No. 2020-555115 entitled “CRYSTALLINE TRANILAST SALTS AND THEIR PHARMACEUTICAL USE”.

NXP002 is the Company’s lead asset and a potential novel inhaled treatment for Idiopathic
Pulmonary Fibrosis (“IPF”). The granted patent describes a proprietary new form 
of the drug tranilast, uniquely enabling delivery via an inhaled nebulised formulation.
Nuformix owns two patent applications relating to crystalline forms of tranilast,
one of which had already been granted globally. This second patent application, 
which as has already been granted in the US, specifically addresses the novel tranilast
forms being progressed by the Company as a potential novel IPF treatment.

> **Dr Dan Gooding, Executive Director of Nuformix plc, said:** _“I’m delighted 
> we have received this Official Decision to Grant from the Japanese Patent Office.
> This provides confirmation that no prior art exists in relation to NXP002, which
> is very important given that this is the territory in which tranilast was first
> invented and where the vast majority of considerable subsequent development work
> has been conducted. The grant is therefore an important step forward for our lead
> asset NXP002. We expect the European grant to follow shortly, which will further
> support the Company’s on-going partnering activities.”_

Nuformix is a pharmaceutical development company targeting unmet medical needs in
fibrosis and oncology via drug repurposing. The Company aims to use its expertise
in discovering, developing and patenting novel drug forms, with improved physical
properties, to develop new products in new indications that are, importantly, differentiated
from the original (by way of dosage, delivery route or presentation), thus creating
new and attractive commercial opportunities. Nuformix has a pipeline of preclinical
assets with potential for significant value and early licensing opportunities.

Share on:
